Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
September 24, 2021 07:00 ET
|
Capricor Therapeutics
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction...
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
September 22, 2021 16:05 ET
|
Capricor Therapeutics
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - - The Cell & Gene Meeting on the Mesa Annual Conference: October 13 - LOS ANGELES, Sept. 22, 2021 (GLOBE NEWSWIRE) --...
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 09:00 ET
|
Capricor Therapeutics
LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
September 02, 2021 08:30 ET
|
Capricor Therapeutics
LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and...
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 16:01 ET
|
Capricor Therapeutics
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase...
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
August 05, 2021 09:00 ET
|
Capricor Therapeutics
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
August 04, 2021 08:00 ET
|
Capricor Therapeutics
-Preclinical Data Demonstrates Capricor’s Exosome Product as an Antishock Therapeutic if Delivered Early -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS...
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
July 27, 2021 08:00 ET
|
Capricor Therapeutics
LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
June 17, 2021 09:00 ET
|
Capricor Therapeutics
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
June 10, 2021 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...